Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy

European Journal of Nuclear Medicine
R A Valdés OlmosH van Tinteren

Abstract

Recognition of adverse late cardiac effects from cancer therapy may enable identification of patients with risk of cardiotoxicity upon cancer retreatment. In this study the feasibility of using iodine-123 metaiodobenzylguanidine (123I-MIBG) heart scintigraphy to detect abnormalities of the myocardial adrenergic neurone function in the late period after cancer therapy was evaluated in relation to the left ventricle ejection fraction (LVEF) in 18 cancer patients: 11 had undergone thoracic irradiation involving the heart, in five cases in combination with anthracycline therapy, 11-228 months (median 60 months) before radionuclide tests, while seven had not received previous anthracycline and/or radiotherapy (controls). The 123I-MIBG cardiac uptake, expressed as a heart-to-mediastinum ratio on planar images after 4h, ranged from 1.21 to 1.76 (median 1.56) in cancer therapy patients, which was significantly decreased (P=0.0006) in comparison with controls (range 1.81- 2.06, median 1.9). The myocardial 123I-MIBG washout, calculated from planar images after 15 min and 4 h, and LVEF also showed significant differences, but with some overlap in individual cases. In cancer therapy patients, cardiac abnormalities seen on planar images and...Continue Reading

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·N A FrankenJ Wondergem
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Nov 1, 1990·CA: a Cancer Journal for Clinicians·W A Bleyer
Nov 1, 1985·International Journal of Radiation Oncology, Biology, Physics·G W MorganR W Giles
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R A Valdés OlmosC A Hoefnagel
Mar 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ValagussaG Bonadonna
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E Lipshultz, S E Sallan
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L HancockR T Hoppe

❮ Previous
Next ❯

Citations

Sep 4, 2007·Cancer Treatment Reviews·Elzbieta Senkus-Konefka, Jacek Jassem
Aug 17, 1999·Cancer Treatment Reviews·M T MeinardiD T Sleijfer
Mar 3, 2017·Clinical Physiology and Functional Imaging·Adam H LaursenRasmus S Ripa
Apr 12, 2017·Antioxidants & Redox Signaling·Carlo Gabriele TocchettiGiuseppe Mercuro
Dec 8, 2007·Expert Review of Anticancer Therapy·Patrick J PerikElisabeth G E de Vries
Mar 1, 1997·European Journal of Nuclear Medicine·G GyenesL E Rutqvist
Dec 21, 2018·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Adam Høgsbro LaursenJens Jakob Thune

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.